Equilis Prequenza Te

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
10-12-2020
Karakteristik produk Karakteristik produk (SPC)
10-12-2020

Bahan aktif:

equine influenza-virus strains: A/equine-2/South Africa/4/03, A/equine-2/Newmarket/2/93, tetanus toxoid

Tersedia dari:

Intervet International BV

Kode ATC:

QI05AL01

INN (Nama Internasional):

vaccine against equine influenza and tetanus in horses

Kelompok Terapi:

Horses

Area terapi:

equine influenza virus + clostridium

Indikasi Terapi:

Active immunisation of horses from six months of age against equine influenza to reduce clinical signs and virus excretion after infection, and active immunisation against tetanus to prevent mortality.

Ringkasan produk:

Revision: 10

Status otorisasi:

Authorised

Tanggal Otorisasi:

2005-07-08

Selebaran informasi

                                14
B.
PACKAGE LEAFLET
15
PACKAGE LEAFLET:
Equilis Prequenza Te suspension for injection for horses
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE,
IF DIFFERENT
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza Te suspension for injection for horses
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Each dose of 1 ml contains:
ACTIVE SUBSTANCES
Equine influenza virus strains:
A/equine-2/ South Africa/4/03 50 AU
1
A/equine-2/ Newmarket/2/93
50 AU
Tetanus toxoid
40 Lf
2
1
Antigenic ELISA units
2
Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig
serum in the Ph.Eur. potency test
ADJUVANT
Iscom Matrix containing:
Purified saponin
375 micrograms
Cholesterol
125 micrograms
Phosphatidylcholine
62.5 micrograms
Clear opalescent suspension.
4.
INDICATION(S)
Active immunisation of horses from 6 months of age against equine
influenza to reduce clinical signs and virus
excretion after infection, and active immunisation against tetanus to
prevent mortality.
Influenza
Onset of immunity:
2 weeks after the primary vaccination course
Duration of immunity:
5 months after the primary vaccination course
12 months after the first revaccination
Tetanus
Onset of immunity:
2 weeks after the primary vaccination course
16
Duration of immunity:
17 months after the primary vaccination course
24 months after the first revaccination
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur
at the injection site, regressing within
2 days. Pain at the injection site can occur in rare cases which may
result in temporary functional discomfort
(stiffness). A local reaction exceeding 5 cm and possibly persisting
longer than 2 days may occur in very rare
cases. Fever, sometimes accompanied by lethargy and inappetence, may
in very rare cases occur for 1 day,
and up to 3 days in exceptio
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza Te suspension for injection for horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
Equine influenza virus strains:
A/equine-2/ South Africa/4/03
50 AU
1
A/equine-2/ Newmarket/2/93
50 AU
Tetanus toxoid
40 Lf
2
1
Antigenic units
2
Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig
serum in the Ph.Eur. potency test
ADJUVANTS:
Iscom-Matrix containing:
Purified Saponin
375 micrograms
Cholesterol
125 micrograms
Phosphatidylcholine
62.5 micrograms
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Clear opalescent suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of horses from 6 months of age against equine
influenza to reduce clinical signs and virus
excretion after infection, and active immunisation against tetanus to
prevent mortality.
Influenza
Onset of immunity:
2 weeks after the primary vaccination course
Duration of immunity:
5 months after the primary vaccination course
12 months after the first revaccination
Tetanus
Onset of immunity:
2 weeks after the primary vaccination course
Duration of immunity:
17 months after the primary vaccination course
24 months after the first revaccination
4.3
CONTRAINDICATIONS
3
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Foals should not be vaccinated before the age of 6 months, especially
when born to mares that were
revaccinated in the last two months of gestation, because of possible
interference by maternally derived
antibodies.
Vaccinate healthy animals only.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or the
label to the ph
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 10-12-2020
Karakteristik produk Karakteristik produk Bulgar 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Bulgar 23-05-2013
Selebaran informasi Selebaran informasi Spanyol 10-12-2020
Karakteristik produk Karakteristik produk Spanyol 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Spanyol 23-05-2013
Selebaran informasi Selebaran informasi Cheska 10-12-2020
Karakteristik produk Karakteristik produk Cheska 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Cheska 23-05-2013
Selebaran informasi Selebaran informasi Dansk 10-12-2020
Karakteristik produk Karakteristik produk Dansk 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Dansk 23-05-2013
Selebaran informasi Selebaran informasi Jerman 10-12-2020
Karakteristik produk Karakteristik produk Jerman 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Jerman 23-05-2013
Selebaran informasi Selebaran informasi Esti 10-12-2020
Karakteristik produk Karakteristik produk Esti 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Esti 23-05-2013
Selebaran informasi Selebaran informasi Yunani 10-12-2020
Karakteristik produk Karakteristik produk Yunani 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Yunani 23-05-2013
Selebaran informasi Selebaran informasi Prancis 10-12-2020
Karakteristik produk Karakteristik produk Prancis 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Prancis 23-05-2013
Selebaran informasi Selebaran informasi Italia 10-12-2020
Karakteristik produk Karakteristik produk Italia 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Italia 23-05-2013
Selebaran informasi Selebaran informasi Latvi 10-12-2020
Karakteristik produk Karakteristik produk Latvi 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Latvi 23-05-2013
Selebaran informasi Selebaran informasi Lituavi 10-12-2020
Karakteristik produk Karakteristik produk Lituavi 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Lituavi 23-05-2013
Selebaran informasi Selebaran informasi Hungaria 10-12-2020
Karakteristik produk Karakteristik produk Hungaria 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Hungaria 23-05-2013
Selebaran informasi Selebaran informasi Malta 10-12-2020
Karakteristik produk Karakteristik produk Malta 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Malta 23-05-2013
Selebaran informasi Selebaran informasi Belanda 10-12-2020
Karakteristik produk Karakteristik produk Belanda 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Belanda 23-05-2013
Selebaran informasi Selebaran informasi Polski 10-12-2020
Karakteristik produk Karakteristik produk Polski 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Polski 23-05-2013
Selebaran informasi Selebaran informasi Portugis 10-12-2020
Karakteristik produk Karakteristik produk Portugis 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Portugis 23-05-2013
Selebaran informasi Selebaran informasi Rumania 10-12-2020
Karakteristik produk Karakteristik produk Rumania 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Rumania 23-05-2013
Selebaran informasi Selebaran informasi Slovak 10-12-2020
Karakteristik produk Karakteristik produk Slovak 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Slovak 23-05-2013
Selebaran informasi Selebaran informasi Sloven 10-12-2020
Karakteristik produk Karakteristik produk Sloven 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Sloven 23-05-2013
Selebaran informasi Selebaran informasi Suomi 10-12-2020
Karakteristik produk Karakteristik produk Suomi 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Suomi 23-05-2013
Selebaran informasi Selebaran informasi Swedia 10-12-2020
Karakteristik produk Karakteristik produk Swedia 10-12-2020
Laporan Penilaian publik Laporan Penilaian publik Swedia 23-05-2013
Selebaran informasi Selebaran informasi Norwegia 10-12-2020
Karakteristik produk Karakteristik produk Norwegia 10-12-2020
Selebaran informasi Selebaran informasi Islandia 10-12-2020
Karakteristik produk Karakteristik produk Islandia 10-12-2020
Selebaran informasi Selebaran informasi Kroasia 10-12-2020
Karakteristik produk Karakteristik produk Kroasia 10-12-2020